Oxford BioMedica
Discover Realise

OXB-302

OXB-302, the Group’s CAR-T 5T4 programme, should complete its pre-clinical studies by the end of 2016. Following demonstration of pre-clinical concept, clinical planning is likely to be initiated in line with strategy.